Funding
← Back to your selection

Mission BioCapital

Activity from announced rounds

Activity in this selectionOct 19, 2026 · Jul 22, 2026

Mission BioCapital is the manager whose Platinum Program portfolio includes Enodia and Cloverleaf.

Recorded funding activity

Enodia develops medicines that degrade proteins during synthesis. Cloverleaf engineers transfer RNA for cancer therapies, while EpiBiologics develops antibodies for extracellular-protein degradation. The manager remains distinct from named funds and programs.

Sources
Rounds participated in
2
Confirmed lead rounds
1
All roles disclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$109.6M
2 disclosed · full round size, not this investor’s share

By stage

Seed1
Series A1

By primary sector

Biotech2

By country

Denmark1
United States1

Rounds

2 in this selection
Cloverleaf Bio

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

$33MSeed
Participant